Galena Biopharma (GALE) slips 14% in the post-session after saying it intends to offer common...

|About: Galena Biopharma, Inc. (GALE)|By:, SA News Editor

Galena Biopharma (GALE) slips 14% in the post-session after saying it intends to offer common stock and warrants for an unspecified amount. The company intends to use the net proceeds to conduct ongoing clinical trials for NeuVax and its Folate Binding Protein-E39. Piper Jaffray is acting as the sole book-running manager for the offering.